Learn how measuring cell avidity enables researchers to quickly identify superior CAR-NK candidates with improved in vivo tumor control
Tumors are often able to escape from immune surveillance using trogocytosis, a mechanism where innate cells accumulate inhibitory molecules torn from the tumor. Recent work using cell avidity measurements by the Gottschalk lab at St. Jude Children’s Research Hospital (published in Nature Biotechnology) and the Rezvani lab at MD Anderson Cancer Center (published in Nature Medicine) revealed new mechanisms to overcome trogocytosis-mediated escape and improve solid tumor clearance in vivo.
Get insights from the expert!
Dr. Chockley presented his work published in Nature Biotechnology “Augmenting CAR NK cell Anti-tumor Activity by Synapse Tuning”.
Leading research teams reveal cell avidity of CAR-NK cells as the best and earliest predictive biomarker for 𝙞𝙣 𝙫𝙞𝙫𝙤 tumor control
Key findings from Chockley et al, 2023 in Nature Biotechnology and Li et al, 2022 in Nature Medicine show that cell avidity increases in vivo anti-tumor efficiency by tuning synapse interactions.
Scientific Highlights:
- Cell avidity is used to identify CAR-NK cells with improved synapse strength and in vivo tumor clearance, leading to potential improvements in therapeutic efficacy.
- Enhanced avidity helps to overcome trogocytosis-mediated relapse and improves in vivo tumor clearance, thus prolonging the survival rate of CAR-NK cells by tuning synapse interactions.
- High-avidity CAR-NK cells display lower levels of trogocytosis than low-avidity cells.
Schematic figure of the z-Movi workflow depicting measurements of two different immune-cell populations with different avidities to the monolayer of target cells and the resulting avidity curves.
Why use the z-Movi?
Because it is the only tool that allows you to reliably select the best CAR-NK and other immune cell variants, saving you invaluable time and costs.
Find out more about the z-Movi here.
Get exclusive access to the webinar with Dr. Marcela Maus
Watch our webinar to get new insights into successful CAR-T engineering by the CAR expert Dr. Marcela Maus. Learn about cell avidity – a promising novel biomarker that is highly predictive of in vivo tumor killing – and how Dr. Maus uses it in her pioneering research.
Speak with an expert
Want to learn more about the z-Movi Cell Avidity Analyzer? Whether you would like to speak to an expert, request a demo, or simply request more information, we would be happy to connect with you.
Request more information
